Biologic activity of LY5 in sarcoma cell lines. by Peter Y. Yu (4281448)

Glucose-lowering efficacy. by Sungmin Kim (628527)

Subjects:

eGFR values and mean eGFR change after the use of dulaglutide. by Sungmin Kim (628527)

Subjects:

Baseline characteristics. by Sungmin Kim (628527)

Subjects:

The incidence rate of progression from microalbuminuria to proteinuria with dulaglutide use. by Sungmin Kim (628527)

Subjects:

Clinical factors affecting renal response to dulaglutide. by Sungmin Kim (628527)

Subjects:

The IC50 value of Tan in normal esophageal HET-1A cells. by Dong Yang (141041)

Assessment of exoprotein concentration in a 50-mL culture of MH96. by Marion Schoof (11999106)

The T37A substitution increases both H5N6 M1 protein stability and H5N6 viral replication in mammals. by Chenxi Wang (284364)

(a) Tuberculosis (TB) incidence rate of 90 countries in 1990 and (b) TB mortality rate of 28 countries in 1950, according to the BCG vaccination status in 2015. by Kazuo Inoue (302545)

Subject demographic data in five-year buckets. by David Romero-Bascones (14265633)

A representative PCV case of 83 years old man with a 95-month treatment period and 27-month persistent fluid. by Chang-Chi Weng (8362725)

Inactivation of one allele of FT5. by Sophia Bigot (16469992)

Fig 5 - by Sebastian Laudenschlager (19233101)

Subjects:

C2GnT1 gene knockdown decreases C2-O-sLe^X glycoproteins and C2GnT1 activity. by Catherine A. St. Hill (357388)

“…Note the absence of a detected C2GnT1 protein 50 kDa band. (D) We observed a 30–40% decrease in reactivity with CHO-131 mAb by flow cytometry for LS174T and HepG2 cells that contained C2GnT1 shRNA. …”

Differential gene expression assay EC₅₀ values in Huh-7 cells and PHH. by Xuan G. Luong (9761423)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Cry variables. by Sarah E. Maylott (14560785)

“…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”